Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.
about
The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patientsAdhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic optionsClinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-AnalysisMining novel biomarkers for prognosis of gastric cancer with serum proteomicsPrognostic value of preoperative serum tumor markers in gastric cancer.Identification of prognostic factors and surgical indications for metastatic gastric cancer.Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis.Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.Preoperative serum tumor marker levels in gastric cancer.Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer.CA19-9-producing early gastric adenocarcinoma arising in hyperplastic foveolar polyp: a very unique resection caseIdentification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot studyPrognostic significance of tumor markers in T4a gastric cancerThe prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma.Over-expression of Metastasis-associated in Colon Cancer-1 (MACC1) Associates with Better Prognosis of Gastric Cancer PatientsSecond-line chemotherapy for patients with advanced gastric cancer: who may benefit?Diagnostic and prognostic role of serum protein peak at 6449 m/z in gastric adenocarcinoma based on mass spectrometryComparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancerPrognostic values of normal preoperative serum cancer markers for gastric cancer.Prognostic significance of preoperative and postoperative CK19 and CEA mRNA levels in peripheral blood of patients with gastric cardia cancerPanel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancer.Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls.Usefulness of Preoperative Plasma Fibrinogen Versus Other Prognostic Markers for Predicting Gastric Cancer Recurrence.Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases.Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric CancerThe prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy.Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer.Preoperative globulin-to-albumin ratio predicts outcome after curative resection in patients with gastric cancer
P2860
Q21131782-D21620D0-88A0-4DCA-AF12-50A3C3AC0773Q26748666-DEB274CB-5F93-42A5-96D8-4AE8CBD97E25Q26828549-CB5C1A9B-3C72-4D9F-AAEB-2861973A9DC7Q33501377-915E99DD-900A-4C3A-BA78-7F4A4113977AQ33585073-43D0C5C0-7F59-41FF-8D05-7B818ED99404Q33755032-596ABD7E-BFEE-4A15-9B27-2A87BE8549AFQ33813676-D20806D5-3DFF-4259-A1D7-3E5CF59B7B91Q33830752-8DDE8ED9-FF73-4CE1-9CAE-64500C262E1EQ34614931-981AF144-5A68-4578-A7FB-1AD23A2D065DQ34660420-2ABF95B8-3702-4164-BBF5-28AB8AFDE04FQ35560299-19557114-01DB-464E-B69E-F5727DAF93E6Q35773128-25EF2325-77EA-4916-A2CC-17E1461F8DF9Q35777594-409D47C9-0684-4AD1-AC15-2673ED7E7269Q36125529-E990410D-8459-429A-80C6-C5F6B7FE5935Q36191929-DBC2FE0E-EE5E-4E43-894B-11EBD7E0ECD5Q36654661-F03BDBEF-93ED-4ACF-B2D1-5D7630737D82Q36964966-0C903B10-8CF7-4166-8E29-A3B37385A8C6Q37174708-D7DA71AD-1C49-46AD-A95A-328CBD37E9AAQ37386228-7E7A2B68-FBFA-4353-9569-5A97957DB611Q37404845-BE995F83-04CA-471E-9822-DC9065CB8C1CQ37629042-17AF6781-5E95-46B6-AA7E-B89AD81AC591Q37672230-9EEE0C26-C429-48C4-987B-252DF8BCB399Q37735594-4961A241-C0C4-4657-912C-043D65758D7AQ38391277-8DB1A068-0D92-428D-907F-884B2509F46CQ39037474-A2CD632D-B01D-4C7E-9FEB-A9031768A55DQ39926759-93C7B71D-0859-427E-B555-2A5AB7564539Q42878096-F2E68694-ED92-4923-893C-23E7C6B659B7Q45893288-DE7ADD42-2B55-4CAF-AC74-C17205EAC712Q47124055-0600D530-8777-490C-A0E6-AA524577C6C9Q49645479-1C37B76B-51E6-4104-B722-818D58B70E42Q50882005-84CAF16B-E420-47A5-88D5-F4A2B53359CEQ53130326-5FE79E6D-D8CA-422E-876B-6550D7597838Q58779919-822290E1-E381-421E-A11C-C4154EE0A407
P2860
Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@ast
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@en
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@nl
type
label
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@ast
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@en
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@nl
prefLabel
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@ast
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@en
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@nl
P2093
P356
P1433
P1476
Evaluation of serum CEA and CA ...... patients with gastric cancer.
@en
P2093
Fumiro Mochizuki
Kazuo Aizaki
Masashi Fujii
Mitsugu Kochi
Mitsuko Kasahara
Motoo Yamagata
Noriaki Kanamori
Teruo Kaiga
Tetsuya Kawakami
Yuichi Kasakura
P2888
P304
P356
10.1007/PL00011715
P577
2000-12-01T00:00:00Z
P5875
P6179
1020317859